chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; Chills; Sore throat; Headache; Body ache; Stomach ache; This is a spontaneous report from a contactable consumer, the patient, A 41-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 06:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 11:00 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. On 16Apr2021 at 15:00, the patient experienced fever, chills, sore throat, headache, body ache and stomach ache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, sore throat, headache, body ache and stomach ache was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Chills, Headache, Myalgia, Pyrexia
Clinical narrative: Fever; Headache; Chills; Chest pain; Muscle pain; Site injection pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the right arm on 17Apr2021 at 09:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 27Mar2021 at 16:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 21:00, the patient experienced fever, headache, chills, chest pain, muscle pain and site injection pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of fever, headache, chills, chest pain, muscle pain and site injection pain was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Fever; Headache; Chills; Chest pain; Muscle pain; Site injection pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the right arm on 17Apr2021 at 09:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 27Mar2021 at 16:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 21:00, the patient experienced fever, headache, chills, chest pain, muscle pain and site injection pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of fever, headache, chills, chest pain, muscle pain and site injection pain was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Chest pain, Heart rate
Clinical narrative: 1st evening after vaccination "I" started to feel small pain in the left part of "my" chest, "I" measured bpm by "my"  phone and it was 51. Next day evening "I" had medium pain in the mid left part of "my" chest and same 50-51 bpm.; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 16Apr2021 at 16:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included lifitegrast (XIIDRA) eye drops for an unknown indication from an unknown date and unknown if ongoing. On 16Apr2021 at 21:00, 1st evening after vaccination, the patient started to felt small pain in the left part of the chest. Next day evening, the patient had medium pain in the mid left part of the chest with 50-51 bpm. It was reported that low blood pressure was normal for the patient and she had requested an appointment with her physician. On 16Apr2021, the patient underwent heart rate test by her phone and the result was 51 bpm and also underwent blood pressure test and the result was 114/70 on the left arm and 117/75 on the right arm. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event small pain in the left part of the chest and medium pain in the mid left part of chest was resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dyspnoea, Nausea
Clinical narrative: Diarrhea; Nausea; Shortness of breath; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CR8734) via an unspecified route of administration in the right arm on 05Apr2021 at 16:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atenolol (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN), ergocalciferol (VIT D) and multivitamin (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 08Mar2021 at 16:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 12Apr2021, the patient experienced diarrhea, nausea and shortness of breath. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events diarrhea, nausea and shortness of breath were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, Urticaria
Clinical narrative: Hives; Itchy rash; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 07Apr2021 at 09:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included bupropion hydrochloride (WELLBUTRIN) for an unknown indication from an unknown date and unknown if ongoing. On 09Apr2021 at 17:00, the patient experienced hives and itchy rash. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with antihistamines and steroid cream. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events hives and itchy rash were unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 62-year-old female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 62, via an unspecified route of administration, in the left arm, on Mar 28, 2021, at 11:00, single dose, for COVID-19 immunisation. Medical history included vertigo. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient has no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 62, via an unspecified route of administration, in the left arm, on Feb 7, 2021, at 00:00, single dose, for COVID-19 immunisation. On Apr 14, 2021 at 02:00, patient was extremely dizzy for 2 weeks. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The outcome of extremely dizzy for 2 weeks: not recovered (at the time of this report). No follow-up attempts required. Information about batch/lot number cannot be obtained. No further information expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Chills, Fatigue, Headache
Clinical narrative: then experienced flu like symptoms the following day around 10:00 am; Sore shoulder about 2 hours after shot; Exhausted; Weak; Chills; Headache; Feverish; Joint aches; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 16Apr2021 at 14:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the left arm on 26Mar2021 at 14:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. On 16Apr2021 about 2 hours after the shot, the patient experienced sore shoulder. On 17Apr2021 the following day around 10:00, the patient experienced flu like symptoms. On an unknown date in Apr2021, the patient experienced exhausted, weak, joint aches, chills, headache and feverish. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events exhausted, weak, chills, headache, feverish, sore shoulder, joint aches and flu like symptoms were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza like illness, Pyrexia
Clinical narrative: then experienced flu like symptoms the following day around 10:00 am; Sore shoulder about 2 hours after shot; Exhausted; Weak; Chills; Headache; Feverish; Joint aches; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 16Apr2021 at 14:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the left arm on 26Mar2021 at 14:15 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. On 16Apr2021 about 2 hours after the shot, the patient experienced sore shoulder. On 17Apr2021 the following day around 10:00, the patient experienced flu like symptoms. On an unknown date in Apr2021, the patient experienced exhausted, weak, joint aches, chills, headache and feverish. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events exhausted, weak, chills, headache, feverish, sore shoulder, joint aches and flu like symptoms were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity, Pyrexia
Clinical narrative: This is a spontaneous report from a noncontactable consumer (patient). A 33-year-old male patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EP6955), at the age of 33, via an unspecified route of administration, in the left arm, on Apr 17, 2021, at 13:00, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EP6955), at the age of 33, via an unspecified route of administration, in the left arm, on Mar 29, 2021, at 16:00, single dose, for COVID-19 immunisation. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 18, 2021 at 01:00, patient experienced severe arm pain followed by fever, headache and fatigue. No therapeutic measures taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, patient has not tested for COVID-19. The outcome of severe arm pain followed by fever, headache and fatigue: resolving (at the time of this report). No follow-up attempts possible. No further information expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Migraine
Clinical narrative: Severe migraine, I suffer from chronic migraines and this headache is worse than any I have ever had; Also having some shortness of breath.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 16Apr2021 at 09:15(at the age of 64-years-old) as a single dose for COVID-19 immunisation. The medical history included multiple sclerosis(MS), chronic migraine, neck fusion, high BP and eye problems. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other unspecified medications within two weeks of vaccination. The patient previously took pregabalin (LYRICA), Triiodothyronine (T3) on an unknown date and experienced allergy. On 16Apr2021 at 15:00, the patient experienced severe migraine, suffered from chronic migraines and this headache was worse than any he ever had. It was been three days straight now and was also having some shortness of breath. The adverse event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether the patient received any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe migraine, suffered from chronic migraines and this headache was worse than any it ever had and shortness of breath was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Left arm pit swelling, possibly the lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 15Apr2021 at 15:15, as a single dose for COVID-19 immunisation. Medical history and Concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks, prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 25Mar2021 at 15:15, as a single dose for COVID-19 immunisation. On 16Apr2021 at 06:00, the patient experienced left arm pit swelling, possibly the lymph nodes. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left arm pit swelling, possibly the lymph nodes was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Rash, SARS-CoV-2 test
Clinical narrative: Full body rash that developed over a period of two days; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK8733) via an unspecified route of administration in the arm left on 06Apr2021 at 09:00 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Medical history included allergies to scallops and bee venom. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. On 09Apr2021, the patient experienced full body rash that developed over a period of two days. On 15Apr2021, the patient underwent SARS-CoV-2 test and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of rash and included treatment with benadryl (MANUFACTURER UNKNOWN). Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event rash was recovering at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Myalgia, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 16Apr2021 at 16:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included ADHD (attention deficit hyperactivity disorder), anxiety, depression and seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient received unspecified medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 26Mar2021 at 19:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021, within 24 hours of the second shot, the patient experienced chills, muscle aches, fatigue and fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events chills, muscle aches, fatigue and fever was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Headache, Myalgia, Pyrexia
Clinical narrative: 101 degrees F fever; severe headache; muscle pain; joint pain; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 08:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram oxalate (LEXAPRO) of dose 10mg taken for unknown indication from an unknown date and unknown if ongoing. On 03Apr2021 at 00:00, the patient experienced 101 degrees F fever, severe headache, muscle pain and joint pain. On the same day, the patient underwent body temperature test and the result was 101 degree Fahrenheit. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19.The clinical outcome of the events 101 degrees F fever, severe headache, muscle pain and joint pain was unknown at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 08:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Chills, Diarrhoea, Ear pain
Clinical narrative: Severe headache; Severe arm pain; Chills; Nausea; Diarrhea; Weakness; Muscle pain; Joint pain; Earache; Sore throat; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 14Apr2021 at 16:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, hypothyroidism, uncomplicated diabetes, bipolar disorder, anxiety disorder, acid reflux, irritable bowel syndrome (IBS), penicillin allergy, allergy to citrus and milk allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN); levothyroxine (MANUFACTURER UNKNOWN); glipizide (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN) and unspecified L (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received amitriptyline (MANUFATURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. On 14Apr2021 at 20:00, the patient experienced severe headache, severe arm pain, chills, nausea, diarrhea, weakness, muscle pain, joint pain, earache and sore throat. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe headache, severe arm pain, chills, nausea, diarrhea, weakness, muscle pain, joint pain, earache and sore throat was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Nausea, Oropharyngeal pain, Pain in extremity
Clinical narrative: Severe headache; Severe arm pain; Chills; Nausea; Diarrhea; Weakness; Muscle pain; Joint pain; Earache; Sore throat; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 14Apr2021 at 16:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, hypothyroidism, uncomplicated diabetes, bipolar disorder, anxiety disorder, acid reflux, irritable bowel syndrome (IBS), penicillin allergy, allergy to citrus and milk allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN); levothyroxine (MANUFACTURER UNKNOWN); glipizide (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN) and unspecified L (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received amitriptyline (MANUFATURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. On 14Apr2021 at 20:00, the patient experienced severe headache, severe arm pain, chills, nausea, diarrhea, weakness, muscle pain, joint pain, earache and sore throat. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe headache, severe arm pain, chills, nausea, diarrhea, weakness, muscle pain, joint pain, earache and sore throat was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Back pain, Body temperature, Chills, Headache
Clinical narrative: Headache; Back ache; Sore left arm/armpit; Sore left arm/armpit; Nausea; Chills; Fever; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0169) via an unspecified route of administration in the left arm on 14Apr2021 at 16:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, depression, and allergy to orange juice. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other unspecified medications in two weeks. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER873) via an unspecified route of administration in the left arm on 24Mar2021 at 16:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 03:00, the patient experienced headache, back ache, sore left arm or armpit, nausea, chills and fever (101.6). On 15Apr2020, the patient underwent body temperature test and the result was 101.6 (unspecified units). The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, back ache, sore left arm or armpit, nausea, chills and fever were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity, Pyrexia
Clinical narrative: Headache; Back ache; Sore left arm/armpit; Sore left arm/armpit; Nausea; Chills; Fever; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0169) via an unspecified route of administration in the left arm on 14Apr2021 at 16:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, depression, and allergy to orange juice. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other unspecified medications in two weeks. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER873) via an unspecified route of administration in the left arm on 24Mar2021 at 16:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 03:00, the patient experienced headache, back ache, sore left arm or armpit, nausea, chills and fever (101.6). On 15Apr2020, the patient underwent body temperature test and the result was 101.6 (unspecified units). The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, back ache, sore left arm or armpit, nausea, chills and fever were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Erythema, Fatigue, Malaise, Nausea
Clinical narrative: Very sick; Nausea; Tired; Chills; Broke out with a reaction on my entire body. Redness; Broke out with a reaction on my entire body. Redness and Itchy; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 13Apr2021 at 11:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and the patient had a foreign variant of the virus in Dec2020. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) and atorvastatin calcium (LIPITOR), both taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 11:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On an unknown date in Apr2021, first 48, the patient experienced very sick, nausea, tired, chills etc. On an unknown date in Apr2021, 24 hours, the patient experienced that a reaction broke out on her entire body, redness and itchy. These symptoms were only after the second shot. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sick, nausea, tired, chills etc., reaction on her entire body, redness and itchy were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Very sick; Nausea; Tired; Chills; Broke out with a reaction on my entire body. Redness; Broke out with a reaction on my entire body. Redness and Itchy; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 13Apr2021 at 11:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and the patient had a foreign variant of the virus in Dec2020. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) and atorvastatin calcium (LIPITOR), both taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 11:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On an unknown date in Apr2021, first 48, the patient experienced very sick, nausea, tired, chills etc. On an unknown date in Apr2021, 24 hours, the patient experienced that a reaction broke out on her entire body, redness and itchy. These symptoms were only after the second shot. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sick, nausea, tired, chills etc., reaction on her entire body, redness and itchy were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia
Clinical narrative: Loss of taste; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 14Apr2021 at 12:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included sarcoidosis, fibromyalgia and known allergies to penicillin and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included tramadol (MANUFACTURER UNKNOWN), estradiol (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN) and prednisone (MANUFACTURER UNKNOWN); all for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 22Mar2021 at 10:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 00:00, the patient experienced loss of taste. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the event. Since the vaccination, the patient had not tested for COVID-19. The clinical outcome of the events loss of taste was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Headache, SARS-CoV-2 test
Clinical narrative: Extreme weakness; Headaches; Lightheadedness; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 14:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 from an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within 2 weeks of vaccination. On an unknown date, the patient experienced 10 days of extreme weakness, headaches and light headedness. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On 12Apr2021, the patient underwent SARS-CoV-2 test (nasal swab) and the result was negative. The clinical outcome of the events extreme weakness, headaches and light headedness were recovered on an unknown date.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dysgeusia, Fatigue, Headache, Nasal congestion
Clinical narrative: Head cold Like stuffy nose; Runny nose; Sneezing; Head cold Like stuffy nose; Could taste the chemicals from the vaccine in ''my'' mouth; Headache; Tiredness; Arm ache; Body aches; Chills; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 14:45 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received sulfamethoxazole/trimethoprim (BACTRIM), for unknown indication on an unknown date and experienced drug allergy. On 15Apr2021 at 15:00, the patient experienced taste the chemicals from the vaccine in her mouth. On the 1st day Thursday (15Apr2021 at 15:00), she got headache, tiredness, arm ache, body aches, chills. The 2nd day Friday (16Apr2021), she woke up with a head cold like stuffy nose, runny nose and sneezing all day along with the 1st day symptoms. On Saturday (17Apr2021), she still had a headache and body ache. On Sunday (18Apr2021), she still had a headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events taste chemical, body ache, tiredness, arm ache, chills, head cold like stuffy nose, runny nose and sneezing was recovered with sequelae on an unknown date in Apr2021, while that of headache was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Nasopharyngitis, Pain, Pain in extremity, Rhinorrhoea, Sneezing
Clinical narrative: Head cold Like stuffy nose; Runny nose; Sneezing; Head cold Like stuffy nose; Could taste the chemicals from the vaccine in ''my'' mouth; Headache; Tiredness; Arm ache; Body aches; Chills; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 14:45 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to vaccination, the patient was diagnosed with COVID-19). The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received sulfamethoxazole/trimethoprim (BACTRIM), for unknown indication on an unknown date and experienced drug allergy. On 15Apr2021 at 15:00, the patient experienced taste the chemicals from the vaccine in her mouth. On the 1st day Thursday (15Apr2021 at 15:00), she got headache, tiredness, arm ache, body aches, chills. The 2nd day Friday (16Apr2021), she woke up with a head cold like stuffy nose, runny nose and sneezing all day along with the 1st day symptoms. On Saturday (17Apr2021), she still had a headache and body ache. On Sunday (18Apr2021), she still had a headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events taste chemical, body ache, tiredness, arm ache, chills, head cold like stuffy nose, runny nose and sneezing was recovered with sequelae on an unknown date in Apr2021, while that of headache was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Headache, Pain, Pain of skin
Clinical narrative: Body aches; Skin soreness; Joint pain; Chills; Headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 17Apr2021 at 12:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included spring allergies (seasonal allergy) and soy allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ascorbic acid (VITAMIN C), rainbow lite multi-vitamin (MANUFACTURER UNKNOWN), asthma inhaler (MANUFACTURER UNKNOWN); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 27Mar2021 at 16:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation.  On 18Apr2021 at 04:00, the patient experienced body aches, skin soreness, joint pain, chills and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with acetaminophen (TYLENOL) Since the vaccination, the patient had been tested for COVID-19. On an unknown date (also reported as 13Jan2021), the patient underwent COVID-19 test via nasal swab and the result was negative. The clinical outcome of the events body aches, skin soreness, joint pain, chills and headache was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.